Huawang Technology: Zhang Yancheng, the director, plans to reduce the company's shares by no more than 0.3443%. Huawang Technology announced that Zhang Yancheng, the company's director and senior manager, plans to reduce the company's shares by no more than 1.6 million shares through centralized bidding on the Shanghai Stock Exchange within three months after the announcement date, accounting for 0.3443% of the company's total share capital. The reduction price will be determined according to the market price. Zhang Yancheng currently holds 6,671,700 shares of the company, accounting for 1.4357% of the company's total share capital.Nearly 30 listed companies announced after-hours that their products would be selected, and the tenth batch of centralized drug procurement (centralized drug procurement) organized by the state was opened in Shanghai yesterday. According to incomplete statistics, as of press time, it includes Fuyuan Pharmaceutical, Yifan Pharmaceutical, ST Tiansheng, Hokuriku Pharmaceutical, Haizheng Pharmaceutical, Zhongheng Group, Yuandong Bio, Kelun Pharmaceutical, China Resources Shuanghe, Sinopharm Modern, Lingkang Pharmaceutical, Xuantai Pharmaceutical, Jiuzhou Pharmaceutical, Kang Enbei, Laimei Pharmaceutical, Kanghong Pharmaceutical, Huasen Pharmaceutical, Borui Pharmaceutical, Xianzeng Pharmaceutical. Among them, Kelun Pharmaceutical announced that 12 kinds of drugs, such as sodium acetate Ringer injection, sodium bicarbonate Ringer injection and gliclazide tablets, were to be selected.The self-built valuation model of bank wealth managers has met with "standardization": some institutions have re-adopted the strategy of excess return of the bank's tier-2 capital bonds with the valuation system of China Securities and China Securities, and recently, the regulatory authorities issued a document to the bank wealth management subsidiary, demanding that the self-built valuation model should not be used to smooth the net value fluctuation, and the valuation standards provided by third parties such as China Securities and China Securities should be adopted, and self-inspection and rectification should be carried out. The purpose of this move is to prevent the bank's wealth management subsidiaries from adjusting product income through self-built models, and to carry out "fund pool" business in disguise to ensure market fairness. At present, a number of bank wealth management subsidiaries have received this document, and have begun to adjust the net value calculation methods of day-opening and closed wealth management products, and re-adopt third-party valuation for investment products such as bank tier 2 capital bonds. A person from a bank financing subsidiary told reporters that he heard that the financial supervision department held a small-scale meeting last week, asking the bank financing subsidiary to respect the new asset management rules and not to violate accounting standards. In addition, the relevant departments also require the financial subsidiaries of banks that have used the self-built valuation model to carry out rectification, and the financial subsidiaries that have been notified shall submit corresponding rectification plans and measures reports within one month. In the view of the above-mentioned bank wealth managers, it is not excluded that some bank wealth management subsidiaries have lowered the allocation ratio of bank tier-2 capital bonds due to the influence of regulatory policies, because when the self-built valuation model is "standardized", the strategy of over-allocating bank tier-2 capital bonds to obtain excess returns becomes increasingly difficult when the net product value fluctuates relatively smoothly. (per meridian)
Huabei Pharmaceutical Co., Ltd.: Four kinds of drugs under the company are planned to be selected for national centralized drug procurement. Huabei Pharmaceutical announced that the company and its subsidiary Xiantai Company participated in the tenth batch of national centralized drug procurement, and all four varieties are planned to be selected, including penicillin sodium for injection, piperacillin sodium for injection, ampicillin sodium for injection and sulbactam sodium for injection. The price of the drug to be selected this time has decreased compared with the original sales price. In 2023, the sales income of penicillin sodium for injection was 129 million yuan, accounting for 1.28% of the annual operating income. If the bid is confirmed and the purchase and sale contract is signed, the company will fully guarantee the supply according to the demand of the selected area, and promote the increment of related products in the selected area and the development of the off-standard market.Putin signed a decree to extend the measures to counter the western oil price limit against Russia again. On December 13th, local time, according to the documents published on the Russian legal information portal, Russian President Vladimir Putin has signed an order to extend the special economic measures formulated because western countries impose price limits on Russian oil and petroleum products until June 30th, 2025. Since the law came into effect on February 1, 2023, the validity of the measures has been extended several times. The decree stipulates that if the contract directly or indirectly stipulates the price ceiling set by other countries, it is forbidden to export Russian petroleum and petroleum products according to the contract, and the signed ban applies to all supply stages before delivery to buyers. (CCTV News)The Bank of Italy said that the economy may only grow by 0.5% this year, and the Bank of Italy said in a statement on Friday that the gross domestic product (GDP) will increase by 0.5% in 2024. If seasonal and calendar effects are not taken into account, this figure will increase to 0.7%, but it is lower than the government's estimate of 1% in the budget. In addition, GDP growth is expected to be 0.8% in 2025 and 1.1% in 2026. It is estimated that the unified average inflation rate in the EU will be 1.1% in 2024, which is the same as the estimated value in October, 1.5% in 2025 and 1.6% in 2025.
Joint Statement by the Foreign Ministers of People's Republic of China (PRC) and the Arab Republic of Egypt (full text) and Joint Statement by the Foreign Ministers of People's Republic of China (PRC) and the Arab Republic of Egypt 1. On December 13, 2024, Commissioner the Political Bureau of the Communist Party of China (CPC) Central Committee and Foreign Minister Wang Yi held a strategic dialogue with Egyptian Minister of Foreign Affairs and Immigration Abdul Atti. 2. The two sides exchanged in-depth and comprehensive views on China-Egypt relations and international and regional issues of common concern, and jointly reviewed the development achievements made by the two countries since the establishment of diplomatic relations, especially since the establishment of a comprehensive strategic partnership 10 years ago. 3. The two sides stressed the need to implement the important consensus reached by the two heads of state at their two meetings in 2024, take the "China-Egypt Year of Partnership" as a new starting point, and push bilateral relations to a higher goal of building a community of destiny between China and Egypt facing the new era. The two sides appreciated the many diplomatic, economic, trade, investment, cultural and tourism activities held by the two countries this year to promote and develop bilateral relations in various fields. (Xinhua News Agency)Musk received an ultimatum from the SEC or faced multiple accusations, and the long-term confrontation between the US SEC and Musk escalated again. On December 12th, local time, Alex spiro, a lawyer of Musk, wrote to Gary Gensler, the outgoing chairman of the SEC, accusing the agency of launching an "ulterior motive action" against Musk, and revealed that the SEC had restarted the investigation of Neuralink, a brain-computer interface company owned by Musk. According to the contents of the letter, the SEC asked Musk to accept the settlement agreement within 48 hours and pay the fine, otherwise he would face "multiple accusations". These allegations are related to Musk's stock investment behavior before the acquisition of Twitter (now "X") in 2022, involving trading time and the legality of information disclosure. It was mentioned in the letter that the accusation originated from an investigation that lasted for several years, and the SEC recently issued a subpoena to Musk's lawyer, asking him to provide testimony. Alex spiro said that he had explicitly refused to cooperate and accused the agency of "political motives". Musk also posted a letter from his lawyer to Gary Gensler on social media, with the text "Gary, how could you do this to me" and a crying emoji. Alex spiro also asked in his letter who was directing the SEC's actions. Alex spiro emphasized that the SEC's "harassment" of Musk and its affiliates for six years has deviated from the original intention of seeking the truth and become an improper pressure. At present, the SEC has not commented on this. In addition, the letter said that the SEC also restarted the investigation of Neuralink, a brain-computer interface company owned by Musk. This autumn, the animal protection organization "Committee of Responsible Medical Doctors" and four US congressmen asked the SEC to investigate Neuralink, accusing it of securities fraud through misleading propaganda. (Securities Times)China International Economic Exchange Center held the annual economic conference in China on December 14th, attended by Han Wenxiu of China Finance Office, and the annual economic conference in China on December 14th, with the theme of implementing the spirit of the Central Economic Work Conference and promoting sustained economic recovery. Han Wenxiu from Zhongcai Office, Zhao Chenxin, Deputy Director of National Development and Reform Commission, Sheng Qiuping, Vice Minister of Commerce, and Wang xin, Director of Research Bureau of China People's Bank will give keynote speeches. (China International Economic Exchange Center)